Moderna partners to develop Bundibugyo Ebola vaccine

Moderna said on Monday it has partnered with the ​Coalition for Epidemic Preparedness Innovations ‌to develop a potential vaccine against Bundibugyo ebolavirus, the strain linked to the ongoing ​Ebola outbreak in eastern Democratic ​Republic of Congo.

Under the agreement, CEPI ⁠has committed up to $50 million ​to support preclinical development and early clinical ​testing of Moderna's investigational BDBV vaccine candidate.

CEPI said it would also initially invest up ​to $8.6 million for a shot developed ​by the University of Oxford and manufactured by ‌the ⁠Serum Institute of India, and an initial $3.2 million for a vaccine developed by the International AIDS Vaccine Initiative.

The ​World Health ​Organization ⁠last week recommended prioritizing several experimental drugs, including antibodies, ​antivirals and vaccines, for the ​treatment ⁠and prevention of BDBV.

CEPI is a global partnership working to accelerate the ⁠development ​of vaccines against epidemic ​and pandemic threats.

-Reuters